Business Wire

ANT-GROUP

5.7.2024 12:27:25 CEST | Business Wire | Press release

Share
Ant Group Unveils Cloud-based Cryptographic Computing Platform

Ant Group today unveiled SecretFlow Cloud, its cloud-based cryptographic computing platform, and a suite of cryptographic computing solutions tailored for large language models (LLMs) at the World Artificial Intelligence Conference in Shanghai.

Leveraging integrated software-hardware cryptographic computing technologies, these solutions enable the secure circulation of encrypted data throughout the hosting and inference processes of LLMs, safeguarding the integrity of LLM assets and data security while significantly enhancing data privacy protection. Providers can now encrypt and deploy their LLMs onto cloud environments effortlessly with a single click through its encrypted hosting service, safeguarding their valuable assets from compromise and theft. Meanwhile, the encrypted inference service ensures efficient data security and the protection of trade secrets during interactions with LLMs.

These solutions allow GPUs to perform computing tasks within trusted execution environments, notably reducing the cost and performance disparity between encrypted LLM inference and plaintext operations, providing a more cost-effective approach. The platform also integrates additional technologies such as memory and disk encryption, ensuring end-to-end encryption and secure cross-domain model hosting management. Additionally, a user-friendly remote attestation system allows for smooth verification through web interfaces, minimizing friction for users.

SecretFlow Cloud currently supports both public and private cloud deployments, and is compatible with commonly-used LLMs in the global market. For instance, in a public cloud setup, users can seamlessly build a new professional LLM on SecretFlow Cloud or migrate an existing LLM to the platform, with its secure LLM inference services ready in as few as 10 minutes with just a click. Moreover, users can purchase cryptographic computing resources on demand to meet their needs.

"Data is the most critical element in the application of LLMs, and cryptographic computing technology significantly enhances the utility of data in cross-domain scenarios," noted Dr. Lenx Wei, Vice President and Chief Technology Security Officer at Ant Group. "As LLMs evolve toward specialized professional domains and become essential productivity tools, cryptographic computing will play a vital role, particularly in fully unlocking the value of high-quality, domain-specific data sets."

According to Dr. Wei, while companies often deploy LLMs in private environments to address data security challenges, such methods can incur higher operational costs and compromise both service efficiency and quality, ultimately constraining the potential of LLMs. The cryptographic computing solutions offered by SecretFlow Cloud can effectively resolve these issues.

Looking forward, SecretFlow Cloud aims to further develop its cryptographic computing solutions to ensure data security throughout the full lifecycle of professional LLMs, including their creation, deployment, and service delivery.

Ant Group has been exploring privacy-preserving computing technologies since 2016 and released SecretFlow in 2022 as an open-source privacy-preserving computing framework that features an array of advanced technologies, including multiparty computation, federated learning, Trusted Execution Environments, Homomorphic Encryption, and Differential Privacy. Positioned at the forefront of cryptographic computing, SecretFlow Cloud represents a new generation of privacy-preserving computing technology, poised to overcome pain points in security, cost, and accessibility in data circulation. It offers a solution for instantly harnessing data value, akin to turning on a tap. To date, its technologies have been adopted in industries such as insurance, rural finance, healthcare, public services, and marketing.

About Ant Group

Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240705154761/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye